Entellus Medical, Inc. (NASDAQ:ENTL) – Analysts at William Blair boosted their FY2017 EPS estimates for Entellus Medical in a note issued to investors on Thursday. William Blair analyst K. Krum now anticipates that the medical technology company will earn ($1.33) per share for the year, up from their prior estimate of ($1.53). William Blair also issued estimates for Entellus Medical’s Q4 2017 earnings at ($0.45) EPS, Q1 2018 earnings at ($0.34) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.24) EPS and FY2018 earnings at ($1.15) EPS.

A number of other brokerages also recently weighed in on ENTL. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a research note on Tuesday, October 17th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub raised shares of Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Finally, Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $21.17.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/07/entellus-medical-inc-entl-forecasted-to-post-fy2017-earnings-of-1-33-per-share.html.

Shares of Entellus Medical (NASDAQ:ENTL) opened at $16.80 on Monday. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $20.34. The company has a quick ratio of 3.53, a current ratio of 3.87 and a debt-to-equity ratio of 0.19.

Several institutional investors and hedge funds have recently made changes to their positions in ENTL. Swiss National Bank increased its position in shares of Entellus Medical by 98.9% during the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after acquiring an additional 8,800 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Entellus Medical by 5.6% during the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after acquiring an additional 573 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Entellus Medical by 77.8% during the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after acquiring an additional 185,833 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Entellus Medical by 87.0% during the first quarter. Geode Capital Management LLC now owns 97,417 shares of the medical technology company’s stock valued at $1,344,000 after acquiring an additional 45,310 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Entellus Medical by 53.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 28,330 shares of the medical technology company’s stock valued at $391,000 after acquiring an additional 9,855 shares in the last quarter. 70.25% of the stock is owned by institutional investors.

In related news, VP Stephen R. Paidosh sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $17.54, for a total transaction of $438,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian E. Farley sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total transaction of $791,200.00. The disclosure for this sale can be found here. Insiders have sold 92,150 shares of company stock valued at $1,740,652 in the last ninety days. Insiders own 7.70% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Earnings History and Estimates for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.